Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science

$FHTX
$MRNA
$SANA
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $FHTX alert in real time by email

AI platform combined with autonomous labs will accelerate discovery across every domain of science

Company has raised $200M in seed financing to further develop platform and build first AI Science Factories

CAMBRIDGE, Mass., March 10, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Lila Sciences, a company building the world's first scientific superintelligence platform and fully autonomous labs for life, chemical, and materials sciences. The company, which was founded in Flagship's labs in 2023, is pioneering an advanced form of AI that can not only process vast amounts of data and make predictions, but also assist scientists in designing and conducting new experiments, generating hypotheses and testing them in real-world environments.

Lila has raised $200 million in committed seed capital from Flagship Pioneering, along with General Catalyst, March Capital, ARK Venture Fund, Altitude Life Science Ventures, Blue Horizon Advisors, State of Michigan Retirement System, Modi Ventures and a wholly owned subsidiary of the Abu Dhabi Investment Authority (ADIA) to support the further development of the AI platform, autonomous labs, and infrastructure for rapid scaling.

"Lila's mission to responsibly achieve Scientific Superintelligence is born out of the belief that this is the most important opportunity of our time, and that the leader in this pursuit will be the entity that runs the scientific method at the largest scale, speed and intelligence," said Geoffrey von Maltzahn, Ph.D., Co-Founder and Chief Executive Officer of Lila Sciences and General Partner, Flagship Pioneering.  "To achieve this, we must solve the hard problems to allow AI to autonomously and in a scalable manner run each step – from AI models generating an idea to reducing it to practice with robotics and automation. We've made some incredible progress in only a few years and are at the very beginning of this important mission."

"For all of human history, the method for scientific exploration has been steadfast: we predict, test, learn, create. Yet for all the progress we have made, we still understand only a fraction of the rules that govern the physical world," said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering and Co-Founder and Chairman, Lila Sciences. "With Lila, our hypothesis is that by scaling experimentation, we can unlock emergent abilities and enable discoveries that remain hidden at smaller scales. Lila represents an ambitious undertaking that we believe will accelerate science with enormous benefit to society."

Lila's Autonomous Science platform is designed to, with human guidance, scale and optimize experimentation in any scientific domain by combining generative AI with generalizable, scalable and autonomous AI science units. In just a few years of development, the platform has demonstrated performance in multiple domains that exceed human and existing AI-powered benchmarks, including:

  • LLMs with state-of-the-art reasoning capabilities on important scientific problems and scientific intelligence benchmarks;
  • Generation of optimal genetic medicine constructs that outperform commercially available therapeutics;
  • Discovery and validation of hundreds of novel antibodies, peptides and binders for a broad range of therapeutic targets;
  • Generation of unique non-platinum group metals as catalysts in the production of green hydrogen at a fraction of the cost of current commercial catalysts; and
  • Design of new material for industrial-scale carbon capture with better capacity, thermal stability and kinetic binding than leading products.

The Lila platform will be open to partners across the life and material sciences industries to jointly bring forth solutions in human health and sustainability at a pace and scale beyond today's bounds. 

Molly Gibson, Ph.D., Co-Founder and President, Future Science at Lila Sciences and Origination Partner, Flagship Pioneering added: "AI has already transformed our ability to uncover new insights from existing data. We believe the next frontier in scientific discovery will come from enabling AI to design and run experiments at unprecedented scale. This requires software and hardware innovation in the lab such that, with each iteration of the scientific method, AI systems can orchestrate thousands of experiments simultaneously, systematically building our understanding and accelerating scientific progress. This approach has the potential to advance research across many scientific domains, from healthcare and drug development to agriculture and sustainable resources, and to create resiliency in our domestic R&D efforts."

Lila is led by a team that brings depth and breadth of expertise across diverse fields including AI, security, commercial strategy, organizational effectiveness, robotics and scientific fields spanning biology, chemistry and materials science. Renowned geneticist George Church, Ph.D., will take the role of Chief Scientist. Andrew Beam, Ph.D., serves as the company's CTO, building a leading AI research team that includes Kenneth Stanley, Ph.D., who joins as a Senior Vice President. Rafael Gómez-Bombarelli, Ph.D., is joining the company as CSO of Materials. Christopher Fussell, an author and expert in cross-functional collaboration, serves as the company's President of Operations.  

About Lila Sciences

Lila Sciences is the world's first scientific superintelligence platform and autonomous labs for life, chemical and materials science.  We are pioneering a new age of boundless discovery by building the capabilities to apply AI to every aspect of the scientific method.  We are introducing scientific superintelligence to solve humankind's greatest challenges, enabling scientists to bring forth solutions in human health and sustainability at a pace and scale never experienced before. Lila was founded in Flagship Pioneering's labs in 2023. Learn more about this mission at  www.lila.ai  

About Flagship Pioneering

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $60 billion in aggregate value. Flagship is operating with $14 billion of assets under management as of its latest capital raise, announced in July 2024. The current Flagship ecosystem comprises over 40 companies, including Foghorn Therapeutics (NASDAQ:FHTX), Moderna (NASDAQ:MRNA), Sana Biotechnology (NASDAQ:SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.

Media Contact

Lila Sciences

press@lila.ai

press@flagshippioneering.com

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/flagship-pioneering-unveils-lila-sciences-to-build-superintelligence-in-science-302397198.html

SOURCE Flagship Pioneering

Get the next $FHTX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$FHTX
$MRNA
$SANA

CompanyDatePrice TargetRatingAnalyst
3/18/2025$5.00Mkt Perform → Mkt Outperform
Citizens JMP
3/14/2025$7.00Buy
Jefferies
3/13/2025$40.00Neutral
Citigroup
2/18/2025$111.00 → $45.00Overweight → Equal Weight
Barclays
1/30/2025$10.00Buy
B. Riley Securities
1/29/2025$99.00 → $51.00Buy → Neutral
Goldman
1/8/2025Hold → Buy
TD Cowen
12/18/2024Buy → Hold
Argus
More analyst ratings

$FHTX
$MRNA
$SANA
Press Releases

Fastest customizable press release news feed in the world

See more
  • Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

    Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population Additional updates include new preclinical data for Selective CBP degrader program in combination with chemotherapy and targeted agents and for Selective EP300 degrader program in hematological malignancies Virtual investor event to be held on Tuesday April 29, 2025, at 8 a.m. ET CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by co

    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Flagship Pioneering Announces Agreement Between Pioneering Medicines and Pfizer to Discover Potential Novel, Selective Inhibitors for Autoimmune Disease

    Collaboration leverages Logica, a platform offering from Valo Health and Charles River that directly translates biological insights into optimized small molecules Sixth agreement signed under strategic partnership between Flagship Pioneering and Pfizer to accelerate discovery of innovative compounds that may become medicines targeting unmet needs CAMBRIDGE, Mass., April 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today announced an agreement between Pioneering Medicines, Flagship's in-house drug discovery and development unit, and Pfizer, to discover compounds which may lead to the development of next-generation therapeutics for autoimmune diseases.

    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

    First Logica-identified candidate marks a progression-based milestone in ongoing partnership with Pioneering Medicines, Flagship Pioneering's in-house drug development unit Charles River Laboratories International, Inc. (NYSE:CRL) and Valo Health, Inc. today announced the identification of an advanceable product candidate for the treatment of different forms of lupus and other autoimmune indications with significant unmet need. The discovery is the first using Logica®, an artificial intelligence (AI)-powered drug development solution that translates biological insights into optimized preclinical assets. "Identification of this first lead candidate provides proof-of-concept for Logica as a

    $CRL
    $FHTX
    $MRNA
    $SANA
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

$FHTX
$MRNA
$SANA
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$FHTX
$MRNA
$SANA
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$FHTX
$MRNA
$SANA
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$FHTX
$MRNA
$SANA
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more

$FHTX
$MRNA
$SANA
Leadership Updates

Live Leadership Updates

See more
  • Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

    Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv

    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health

    Owen joins to lead new phase of growth for the medical device company in clinical trial, diagnostic, and reference laboratory applications CAMBRIDGE, Mass., Feb. 19, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and YourBio Health, a pioneer in remote blood collection technology, today announced the appointment of Paul Owen as Chief Executive Officer of YourBio Health and CEO-Partner of Flagship Pioneering. Owen joins YourBio Health and Flagship after a corporate leadership and strategic planning career spanning more than 35 years. He was most r

    $FHTX
    $MRNA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Flagship Pioneering Appoints Angela Hwang as CEO-Partner and Chief Executive Officer of Metaphore Biotechnologies

    CAMBRIDGE, Mass., Nov. 20, 2024 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Metaphore Biotechnologies, a Flagship-founded biotechnology company designing novel therapeutics by combining machine learning and molecular mimicry, today announced that Angela Hwang, MBA, will join Flagship Pioneering as CEO-Partner, and Metaphore as Chief Executive Officer, effective January 1, 2025. Most recently, Hwang served as Chief Commercial Officer and President of the Global Biopharmaceuticals Business at Pfizer. During her tenure at Pfizer, Hwang helped brin

    $FHTX
    $MRNA
    $OMGA
    $SANA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

$FHTX
$MRNA
$SANA
Financials

Live finance-specific insights

See more
  • Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

    First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin

    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates

    Reports third quarter revenues of $1.9 billion, GAAP net income of $13 million and GAAP EPS of $0.03Achieves year-to-date product sales of $2.2 billion; reiterates 2024 expected product sales of $3.0 to $3.5 billionInitiated dosing in two pivotal Phase 3 trials to assess efficacy of investigational mRNA vaccines against norovirus and influenzaAnnounces expansion of its Executive Committee CAMBRIDGE, MA / ACCESSWIRE / November 7, 2024 / Moderna, Inc. (NASDAQ:MRNA) today reported financial results and provided business updates for the third quarter of 2024."During the third quarter, we focused on execution with the launch of our updated COVID-19 and RSV vaccines in markets across the globe. I

    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Moderna to Report Third Quarter 2024 Financial Results on Thursday, November 7, 2024

    CAMBRIDGE, MA / ACCESSWIRE / October 17, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, November 7, 2024 to report its third quarter 2024 financial results, and provide a corporate update.A live webcast of the call will be available under "Events and Presentations" in the Investors section of the Moderna website.Webcast: https://investors.modernatx.comThe archived webcast will be available on Moderna's website approximately two hours after the conference call and will be available for one year following the call.About ModernaModerna is a leader in the creation of the field of mRNA medicine. Through the adv

    $MRNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$FHTX
$MRNA
$SANA
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more